Headquarters- Dehradun, Uttarakhand.
Area served- India.
Key people- Ashok Kumar windlass, Hitesh Windlass and Manoj Kumar windlass.
Products- CDMO, Generic Products.
Revenue- 4,306.95 Cr.
Number of employees- 954.
Windlas Biotech is India’s leading Biotech pharmaceutical company, It was founded in 2001, headquartered in Dehradun, Uttarakhand. The company offers CDMO services from product discovery to product development, manufacturing, licensing and generic products. Ashok Kumar windlass, Hitesh Windlass and Manoj Kumar windlass are the promoters of the company.
Windlas Biotech was started in 2000 and they received a shutdown Manufacturing Facility. Over the past two decades, Windlas Biotech has evolved into a fully integrated Partner providing products and services to leading pharmaceutical companies. The company also created its own branded products that are distributed through its rapidly growing distribution network of more than 500 wholesale across India.
2001- Windlas Biotech has started its first production plant at Dehradun.
2007- The company set up its own brand and marketing division.
2009- Windlas venture into the international markets. Crossed Rs 100 Cr revenue by establishing a Windlas Healthcare plant.
2014- set up the second plant, crossed Rs 200 Cr revenue and cleared the first USFDA inspection.
2015- Windlas Biotech received a private equity investment from Tano Capital.
2016- The company crossed Rs 300 Cr turnover.
2017- Set up the third plant and launched 1st product in the US from Windlas healthcare.
2018- The company raised the 23 million dollars investment from Zydus Cadila in Windlas healthcare.
2019- Buyback of Zydus shares in Windlas healthcare.
Products and services
Windlass Biotech has an innovative products portfolio of generic medicines. The company works in the pharmaceutical formulations contract development and manufacturing organisation (CDMO) segments in India. Windlas Biotech provides services like products development, licensing and manufacturing of generic products. The company also sells it is In-house branded products in the OTC markets and generic. Windlas Biotech business operated in three segments: CDMO products and services, Domestic trade generic and OTC markets, and exports. The company focus on the complex generic products in the chronic therapeutic sectors related to lifestyle regarding disorders.
Windlass Biotech has three manufacturing plants in Dehradun Uttarakhand, with an install capacity of 7063.83 million tablets, 54.46 million pouch and 61.08 million liquid bottles. The company exports its products to the leading pharmaceutical companies like Cadila healthcare limited, Pfizer limited, Emcure pharmaceutical ltd, Sanofi India limited, Intas Pharmaceutical ltd, Systolic laboratories private ltd.
Windlas Biotech plans to raise 401.54 Cr through the public offering, it comprises a fresh issue of Rs 165 Cr and an offer for sale of Rs 236.54 Cr. The IPO will open on 4 August 2021 and close on 6 August 2021. The issue may list on 17 August 2021. The company plans to use raise IPO funds to purchase equipment required to expand its existing facilities at Dehradun plants. Windlas Biotech GMP was around Rs 130, a 28 % premium and shares traded at the premium price of Rs 578 to Rs 590 per equity share on the unlisted market.
- The company is a leading market player in the domestic Pharmaceutical business.
- It has an innovative products portfolio of generic products.
- The company has a strong financial performance track record.
- Windlas has the experience and professional promoters as well as senior management members.
- Windlas Biotech will list its equity shares on August 16, The final issue price has been fixed at Rs 460 per equity share.
- The stock opened at Rs 439 on the BSE and Rs 437 on the National Stock Exchange, over fall 7% premium in share price.
Address- 40/1, Industrial Area, Mohabbewala,
Ashok Kumar windlass
Manoj Kumar windlass